Cargando…
Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study
BACKGROUND: Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study aimed to assess the effectiveness and safety of pyrotinib plu...
Autores principales: | Yang, Yaning, Yang, Guangjian, Li, Weihua, Hao, Xuezhi, Zhang, Shuyang, Ai, Xin, Lei, Siyu, Xu, Haiyan, Wang, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665774/ https://www.ncbi.nlm.nih.gov/pubmed/37740599 http://dx.doi.org/10.1111/1759-7714.15118 |
Ejemplares similares
-
First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022) -
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)
por: Yang, Guangjian, et al.
Publicado: (2022) -
Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice
por: Yang, Yaning, et al.
Publicado: (2022) -
First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
por: Yang, Guangjian, et al.
Publicado: (2022) -
Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors
por: Yang, Guangjian, et al.
Publicado: (2022)